Fund scalp cooling and hair-preserving… · Idea

Scalp cooling reduces chemotherapy-induced alopecia in randomised trials and is cleared by regulators, yet availability depends on charity, geography and unit culture. The proposal is payer coverage and unit-level capacity for scalp cooling for all patients receiving alopecia-inducing regimens who want it, plus trials of adjunctive topical agents, with hair preservation and body-image outcomes measured in registries.

Hypothesis

Universal availability raises use to over half of eligible patients and reduces refusal of alopecia-inducing regimens and treatment-related distress.

Rationale

Alopecia influences treatment choice and self-image; the intervention exists and is safe, and the barrier is purely organisational and financial.

Proposed test

Payer covers scalp cooling in one region; measure uptake, hair preservation rates and refusal of recommended chemotherapy versus a matched region.

Maturity

being tested at scale

Who acts

payer

Cost to try

Small (under $1M)

Years to first evidence

2

Bottlenecks it attacks

Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.

Notes

Protocol upgrade, graded proven but unevenly used. In the SCALP randomised trial, 48 of 95 women with stage I or II breast cancer using a scalp cooling device kept their hair against none of 47 controls (50.5 per cent against 0 per cent), and the trial was stopped early for superiority; only grade 1 and 2 device-related adverse events were reported (Nangia, 2017).
Adoption gap, as measured at one institution: non-White patients with breast cancer receiving chemotherapy there were about six times less likely than White patients to use scalp cooling (Minta, 2026). OnCo found no national figure for how many chemotherapy units offer it.

Key papers

2

rctJAMA 2017changed practice151 citations

SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer

Scalp cooling works, especially for taxane-based regimens, and is safe. The question moved from whether to how to make it available: device time in the chemotherapy chair, staff training, and who pays.

rctJournal of Clinical Oncology 2015389 citations

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Connected

8

Idea
Hepatitis B blood tests before anyone starts systemic cancer treatment, with antiviral tablets for those who need them
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Clear drinks until two hours before an operation, rather than nothing from midnight
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Low-dose olanzapine and generic antiemetic bundles in every guideline and formulary
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Weekly electronic symptom reporting as a standard of care during systemic therapy
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Ice chips in the chair for every bolus fluorouracil and high-dose melphalan infusion
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Make skipping radiotherapy the default for very low-risk breast cancer
Shares Toxicity and quality of life are undervalued and the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Automatic palliative care referral triggered by diagnosis, not by decline
Shares the tags protocol-upgrade, upgrade:proven-unevenly-used.
Idea
Default fertility preservation referral for every patient under 40 before treatment
Shares the tags protocol-upgrade, upgrade:proven-unevenly-used.

Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen

Notes

Key papers

Connected

Similar pages

fronts

technologies

terms

bottlenecks

key papers

Sources

Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen

Notes

Key papers

Connected

Similar pages

fronts

technologies

terms

bottlenecks

key papers

Sources

Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen

Overview

Notes

Key papers

Connected

Similar pages

fronts

technologies

terms

bottlenecks

key papers

Sources

Fund scalp cooling and hair-preserving measures for every alopecia-inducing regimen

Overview

Notes

Key papers

Connected

Similar pages

fronts

technologies

terms

bottlenecks

key papers

Sources